Baxter updates long-term guidance ahead of 2022 investor event

Baxter International (NYSE:BAX) revised its long-term financial guidance on Wednesday ahead of the medical equipment maker’s investor conference.
The event reserved for both in-person and virtual attendees, will be the company’s first since it acquired the MedTech player Hillrom in Dec. 2021.
In conjunction with the conference, Baxter (BAX) updated its 2025 - 25 estimates for constant currency sales growth to 4% – 5% on a compounded annual basis.
The incremental annual revenue synergies are expected to reach up to $200 million by 2025.
The company projects its 2025 adj. operating margin to expand by 350 to 400 basis points compared to the forecast for 2022.
In addition, it expects the free cash flow conversion to exceed 80% by 2025, when Hillrom is expected to add up to $350 million of annual pre-tax cost synergies.
Read about the company’s recently issued financial guidance for this year.